Cited by 2,020Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseasesPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 141 of the 143 references it cites were found in a registry or an index.

Idiopathic pulmonary fibrosis

Richeldi, Luca, Collard, Harold R, Jones, Mark G·2017·The Lancet

DOI 10.1016/s0140-6736(17)30866-8

Open this paper in CoChat — free account

Abstract

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30866-8

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citation
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citation
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,378
Self-citation
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Fleischner Society: Glossary of Terms for Thoracic Imaging
Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Rémy, J. (2008) · Radiology · doi:10.1148/radiol.2462070712 · Cited by 4,189
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,651
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation

Show all 143 references

Research works printed but not linked: 1

2000, Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS), Am J Respir Crit Care Med, 161, 646, 10.1164/ajrccm.161.2.ats3-00 · DOI

Sorted by citations

Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis
Adams, T. S., Schupp, J. C., Poli, S., Ayaub, E. A., Neumark, N., Ahangari, F., Chu, S. G., Raby, B. A., DeIuliis, G., Januszyk, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1983 · Cited by 1,420
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,151
Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
Cottin, V., Hirani, N., Hotchkin, D. L., Nambiar, A. M., Ogura, T., Otaola, M., Skowasch, D., Park, J. S., Poonyagariyagorn, H. K., Wuyts, W. A., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0076-2018 · Cited by 656
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, Τ., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 654
Self-citation
Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Self-citation
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases
Zhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 571
Complex interplay between autophagy and oxidative stress in the development of pulmonary disease
Ornatowski, W., Lü, Q., Yegambaram, M., Flores, A. G., Zemskov, E. A., Maltepe, E., Fineman, J. R., Wang, T., & Black, S. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101679 · Cited by 484
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.023 · Cited by 476
Macrophages in Lung Injury, Repair, and Fibrosis
Cheng, P., Li, S., & Chen, H. (2021) · Cells · doi:10.3390/cells10020436 · Cited by 457
Lung microbiome: new insights into the pathogenesis of respiratory diseases
Li, R., Li, J., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01722-y · Cited by 483
Progressive Pulmonary Fibrosis Is Caused by Elevated Mechanical Tension on Alveolar Stem Cells
Wu, H., Yu, Y., Huang, H., Hu, Y., Fu, S., Wang, Z., Shi, M., Zhao, X., Yuan, J., Li, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.11.027 · Cited by 456
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.170 · Cited by 406
Macrophages: friend or foe in idiopathic pulmonary fibrosis?
Zhang, L., Wang, Y., Wu, G., Xiong, W., Gu, W., & Wang, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0864-2 · Cited by 379
Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function
Yu, G., Τzouvelekis, Α., Wang, R., Herazo‐Maya, J. D., Ibarra, G. H., Srivastava, A., Werneck‐de‐Castro, J. P., DeIuliis, G., Ahangari, F., Woolard, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4447 · Cited by 360
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020) · Pulmonary Medicine · doi:10.1155/2020/6175964 · Cited by 376
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102763 · Cited by 370
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., DeLeon, J. R., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 338
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Ng, B., Dong, J., D’Agostino, G., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Ko, N. S. J., Tan, J., Chothani, S. P., Huang, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1237 · Cited by 314
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30262-0 · Cited by 293
Self-citation
Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model
Pei, Z., Qin, Y., Fu, X., Yang, F., Huo, F., Liang, X., Wang, S., Cui, H., Lin, P., Zhou, G., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102509 · Cited by 273
Epithelial–Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Salton, F., Volpe, M., & Confalonieri, M. (2019) · Medicina · doi:10.3390/medicina55040083 · Cited by 277
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
Spagnolo, P., Distler, O., Ryerson, C. J., Τzouvelekis, Α., Lee, J. S., Bonella, F., Bouros, D. E., Hoffmann‐Vold, A., Crestani, B., & Matteson, E. L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217230 · Cited by 266
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vašáková, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2018) · JAMA · doi:10.1001/jama.2018.6129 · Cited by 239
Self-citation
Role of interleukins in the pathogenesis of pulmonary fibrosis
She, Y. X., Yu, Q. Y., & Tang, X. X. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00437-9 · Cited by 231
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases
Efferth, T., & Oesch, F. (2021) · Medicinal Research Reviews · doi:10.1002/med.21842 · Cited by 225
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R. R. H., Ebner, T., Stopfer, P., & Dallinger, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00766-0 · Cited by 222
Use of precision cut lung slices as a translational model for the study of lung biology
Liu, G., Betts, C., Cunoosamy, D. M., Åberg, P. M., Hornberg, J. J., Sivars, K. B., & Cohen, T. S. (2019) · Respiratory Research · doi:10.1186/s12931-019-1131-x · Cited by 206
Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis
Sheng, G., Chen, P., Wei, Y., Yue, H., Chu, J., Zhao, J., Wang, Y., Zhang, W., & Zhang, H.-L. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.10.032 · Cited by 219
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Olson, A. L., Gifford, A. H., Inase, N., Pérez, E. R. F., & Suda, T. (2018) · European Respiratory Review · doi:10.1183/16000617.0077-2018 · Cited by 201
Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways
Lv, Q., Wang, J., Xu, C., Huang, X., Ruan, Z., & Dai, Y. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00173-3 · Cited by 213
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study
Dressen, A., Abbas, A. R., Cabanski, C. R., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T., Brauer, M. J., Hunkapiller, J., Reeder, J., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30135-8 · Cited by 196
Self-citation
Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management
Luppi, F., Kalluri, M., Faverio, P., Kreuter, M., & Ferrara, G. (2021) · Respiratory Research · doi:10.1186/s12931-021-01711-1 · Cited by 211
The roles of exosomal miRNAs and lncRNAs in lung diseases
Yang, L., Yin, Z., Fan, J., Zhang, S., & Yang, W.-B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0080-7 · Cited by 190
Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge
Bai, X., Zhao, G., Chen, Q., Li, Z., Gao, M., Ho, W., Xu, X., & Zhang, X. (2022) · Science Advances · doi:10.1126/sciadv.abn7162 · Cited by 195
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Lawrence, J., & Nho, R. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183
Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems
Andugulapati, S. B., Gourishetti, K., Tirunavalli, S. K., Shaikh, T. B., & Sistla, R. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153298 · Cited by 183
The epithelial barrier theory and its associated diseases
Sun, N., Öğülür, İ., Mitamura, Y., Yazıcı, D., Pat, Y., Bu, X., Li, M., Zhu, X., Babayev, H., Ardıçlı, S., et al. (2024) · Allergy · doi:10.1111/all.16318 · Cited by 190
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis
Hill, C. N., Li, J., Liu, D., Conforti, F., Brereton, C. J., Yao, L., Zhou, Y., Alzetani, A., Chee, S., Marshall, B. G., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1820-x · Cited by 177
Self-citation
Astragaloside IV modulates TGF ‐β1‐dependent epithelial‐mesenchymal transition in bleomycin‐induced pulmonary fibrosis
Qian, W., Cai, X., Qian, Q., Zhang, W., & Wang, D. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13725 · Cited by 175
Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis
Sun, L., Fan, M., Huang, D., Li, B., Xu, R., Gao, F., & Chen, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120761 · Cited by 178
Quantitative CT Analysis of Diffuse Lung Disease
Chen, A., Karwoski, R. A., Gierada, D. S., Bartholmai, B. J., & Koo, C. W. (2019) · Radiographics · doi:10.1148/rg.2020190099 · Cited by 176
Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway
Inui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study
Röhrich, M., Leitz, D. H. W., Glatting, F. M., Wefers, A. K., Weinheimer, O., Flechsig, P., Kahn, N. C., Mall, M. A., Giesel, F. L., Kratochwil, C., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261925 · Cited by 172
Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts
Guan, R., Liang, Y., Li, J., Wang, J., Li, Z., Cai, Z., Guo, H., Fang, Y., Lin, R., Liu, W. Q., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02307-2021 · Cited by 176
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways
Suryadevara, V., Ramchandran, R., Kamp, D. W., & Natarajan, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124257 · Cited by 171
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis
Jones, M. G., Andriotis, O. G., Roberts, J., Lunn, K., Tear, V. J., Cao, L., Ask, K., Smart, D. E., Bonfanti, A., Johnson, P., et al. (2018) · eLife · doi:10.7554/elife.36354 · Cited by 165
Self-citation
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
Cigarette smoke-inactivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosis
Zhang, Y., Huang, W., Zheng, Z., Wang, W., Yuan, Y., Hong, Q., Lin, J., Li, X., & Meng, Y. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.013 · Cited by 163
TGF-β signaling: critical nexus of fibrogenesis and cancer
Giarratana, A. O., Prendergast, C. M., Salvatore, M. M., & Capaccione, K. M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05411-4 · Cited by 180
Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases
Yang, P., Luo, Q., Wang, X., Fang, Q., Fu, Z., Li, J. X., Lai, Y., Chen, X., Xu, X., Peng, X., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2414oc · Cited by 163
IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages
Rao, L.-Z., Wang, Y., Zhang, L., Wu, G., Zhang, L., Wang, F.-X., Chen, L.-M., Sun, F., Jia, S., Zhang, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00650-6 · Cited by 153
The therapeutic potential of second and third generation CB1R antagonists
Çınar, R., Iyer, M. R., & Kunos, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107477 · Cited by 161
Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential
Smyth, P., Sasiwachirangkul, J., Williams, R. D., & Scott, C. J. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101106 · Cited by 155
Mapping spatially resolved transcriptomes in human and mouse pulmonary fibrosis
Franzén, L., Lindvall, M. O., Hühn, M. H., Ptasinski, V., Setyo, L. C., Keith, B. P., Collin, A., Oag, S., Volckaert, T., Borde, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01819-2 · Cited by 154
Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis
Yao, L., Conforti, F., Hill, C. N., Bell, J., Drawater, L., Li, J., Liu, D., Xiong, H., Alzetani, A., Chee, S., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0175-7 · Cited by 147
Self-citation
Epithelial-Mesenchymal Transition Contributes to Pulmonary Fibrosis via Aberrant Epithelial/Fibroblastic Cross-Talk
Hill, C. N., Jones, M. G., Davies, D. E., & Wang, Y. (2019) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2019/2.1149 · Cited by 147
Self-citation
Precision medicine advances in idiopathic pulmonary fibrosis
Karampitsakos, Τ., Juan-Guardela, B. M., Τzouvelekis, Α., & Herazo‐Maya, J. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104766 · Cited by 148
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review
Junren, C., Xiaofang, X., Huiqiong, Z., Li, G., Yanpeng, Y., Xiaoyu, C., Gao, Y., Li, Y., Zhang, Y., Fu, P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.660757 · Cited by 159
Diesel exhaust PM2.5 greatly deteriorates fibrosis process in pre-existing pulmonary fibrosis via ferroptosis
Yue, D., Zhang, Q., Zhang, J., Liu, W., Chen, L., Wang, M., Li, R., Qin, S., Song, X., & Ji, Y. (2022) · Environment International · doi:10.1016/j.envint.2022.107706 · Cited by 147
Iron oxide nanoparticles augment the intercellular mitochondrial transfer–mediated therapy
Huang, T., Zhang, T., Jiang, X., Li, A., Su, Y., Bian, Q., Wu, H., Lin, R., Li, N., Cao, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0534 · Cited by 144
TGF-β as A Master Regulator of Aging-Associated Tissue Fibrosis
Ren, L.-L., Miao, H., Wang, Y.-N., Liu, F., Li, P., & Zhao, Y.-Y. (2023) · Aging and disease · doi:10.14336/ad.2023.0222 · Cited by 139
Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
Sauleda, J., Núñez, B., Sala, E., & Soriano, J. B. (2018) · Medical Sciences · doi:10.3390/medsci6040110 · Cited by 145
Notch signaling in the mammalian respiratory system, specifically the trachea and lungs, in development, homeostasis, regeneration, and disease
Kiyokawa, H., & Morimoto, M. (2019) · Development Growth & Differentiation · doi:10.1111/dgd.12628 · Cited by 133
Alveolar and lung interstitial macrophages: Definitions, functions, and roles in lung fibrosis
Shi, T., Denney, L., An, H., Ho, L., & Zheng, Y. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru0720-418r · Cited by 146
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Michalski, J. E., Kurche, J. S., & Schwartz, D. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.09.001 · Cited by 139
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Estornut, C., Milara, J., Bayarri, M. A., Belhadj, N., & Cortijo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794997 · Cited by 138
ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling
Liu, J., Wu, Z., Liu, Y., Zhan, Z., Yang, L., Wang, C., Jiang, Q., Ran, H., Li, P., & Wang, Z. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01435-4 · Cited by 134
Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis
Cheng, H., Feng, D., Li, X., Gao, L., Tang, S., Liu, W. Q., Wu, X., Yue, S., Li, C., & Luo, Z. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166204 · Cited by 132
The cGAS‐STING pathway: The role of self‐DNA sensing in inflammatory lung disease
Ma, R., Serrano, T. P. O., Davis, J., Prigge, A. D., & Ridge, K. M. (2020) · The FASEB Journal · doi:10.1096/fj.202001607r · Cited by 138
Macrophage polarization and its impact on idiopathic pulmonary fibrosis
Ge, Z., Chen, Y. Q., Ma, L., Hu, F., & Xie, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444964 · Cited by 147
Deep Learning–based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography
Walsh, S. L. F., Mackintosh, J. A., Calandriello, L., Silva, M., Sverzellati, N., Larici, A. R., Humphries, S. M., Lynch, D. A., Jo, H. E., Glaspole, I., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2684oc · Cited by 132
Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis
Cui, F., Sun, Y., Xie, J., Li, D., Wu, M., Song, L., Hu, Y., & Tian, Y. (2022) · European Respiratory Journal · doi:10.1183/13993003.00777-2022 · Cited by 139
Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFβ signaling through TGFBR1 stabilization
Lee, T.-H., Yeh, C., Lee, Y.-T., Shih, Y.-C., Chen, Y.-T., Hung, C., You, M.-Y., Wu, P., Shentu, T., Huang, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18047-x · Cited by 131
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104304 · Cited by 129
The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
Liu, S., Liu, C., Lv, X., Cui, B., Yan, J., Li, Y., Li, K., Hua, F., Zhang, X., Yu, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.008 · Cited by 125
Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Zheng, Q., Cox, I. A., Campbell, J. A., Xia, Q., Otáhal, P., de Graaff, B., Corte, T. J., Teoh, A. K. Y., Walters, E. H., & Palmer, A. J. (2022) · ERJ Open Research · doi:10.1183/23120541.00591-2021 · Cited by 126
Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways
Zhang, Y., Lu, W.-T., Zhang, X., Lü, J., Xu, S., Chen, S., Zhong, Z., Zhou, T., Wang, Q., Chen, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104307 · Cited by 121
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases
Brindisi, M., Saraswati, A. P., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00924 · Cited by 123
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., Kasselman, L. J., Glass, A. D., DeLeon, J. R., & Reiss, A. B. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.002 · Cited by 132
A Biomimetic Human Lung‐on‐a‐Chip with Colorful Display of Microphysiological Breath
Zhu, Y., Sun, L., Wang, Y., Cai, L., Zhang, Z., Shang, Y., & Zhao, Y. (2022) · Advanced Materials · doi:10.1002/adma.202108972 · Cited by 121
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 122
Tobacco Smoking and Risk for Pulmonary Fibrosis
Bellou, V., Belbasis, L., & Εvangelou, Ε. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.04.035 · Cited by 127
New Insights into Hippo/YAP Signaling in Fibrotic Diseases
Mia, M. M., & Singh, M. K. (2022) · Cells · doi:10.3390/cells11132065 · Cited by 120
Hesperidin inhibits lung fibroblast senescence via IL-6/STAT3 signaling pathway to suppress pulmonary fibrosis
Han, D., Gong, H., Wei, Y., Xu, Y., Zhou, X., Wang, Z., & Feng, F. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154680 · Cited by 118
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis
Ahangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K. M., Wang, X., Justet, A., Adams, T. S., Readhead, B. P., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202010-3832oc · Cited by 119
circHIPK3 regulates lung fibroblast-to-myofibroblast transition by functioning as a competing endogenous RNA
Zhang, J., Lu, J. L., Xie, H., Wang, D.-P., Ni, H., Zhu, Y., Ren, L., Meng, X., & Wang, R. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1430-7 · Cited by 114
Macrophages in lung fibrosis
Ogawa, T., Shichino, S., Ueha, S., & Matsushima, K. (2021) · International Immunology · doi:10.1093/intimm/dxab040 · Cited by 113
Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis
Campa, C. C., Silva, R. L., Margaria, J. P., Pirali, T., Mattos, M. S., Kraemer, L. R., dos Reis, D. C., Grosa, G., Copperi, F., Dalmarco, E. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07698-6 · Cited by 113
[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity
Rosenkrans, Z. T., Massey, C. F., Bernau, K., Ferreira, C. A., Jeffery, J. J., Schulte, J. J., Moore, M. D., Valla, F., Batterton, J. M., Drake, C. R., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05814-9 · Cited by 113
HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
Yoon, S., Kang, G., & Eom, G. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061329 · Cited by 112
Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics
Pokharel, M. D., Flores, A. G., Marciano, D. P., Franco, M. C., Fineman, J. R., Aggarwal, S., Wang, T., & Black, S. M. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103049 · Cited by 124
X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology
Katsamenis, O. L., Olding, M., Warner, J. A., Chatelet, D. S., Jones, M. G., Sgalla, G., Smit, B., Larkin, O. J., Haig, I. G., Richeldi, L., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.05.004 · Cited by 109
Self-citation
Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
Wang, Y., Huang, B., Jin, T., Ocansey, D. K. W., Jiang, J., & Mao, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835005 · Cited by 112
Role of imaging in progressive-fibrosing interstitial lung diseases
Walsh, S. L. F., Devaraj, A., Enghelmayer, J. I., Kishi, K., Silva, R. S., Patel, N. M., Rossman, M. D., Valenzuela, C., & Vancheri, C. (2018) · European Respiratory Review · doi:10.1183/16000617.0073-2018 · Cited by 107
Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations
Gea, J., Sancho‐Muñoz, A., & Chalela, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.66 · Cited by 111

Authors: Richeldi, L., Collard, H. R., & Jones, M. G.
Affiliations: Università Cattolica del Sacro Cuore (IT)
University of California, San Francisco (US)
National Institute for Health and Care Research (GB)
Corresponding author: Richeldi, Luca
ORCID: Richeldi, Luca
Collard, Harold R
Jones, Mark G
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-05
Volume: 389
Issue: 10082
Pages: 1941-1952
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30866-8
OpenAlex: W2599075603
Cited by: 2,020
References: 143
Citations by year: 2026: 202 · 2025: 317 · 2024: 338 · 2023: 293 · 2022: 273 · 2021: 233 · 2020: 167 · 2019: 94 · 2018: 76 · 2017: 22
FWCI: 17.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (acceptedVersion)
Funders: National Institute for Health and Care Research (CL-2016-26-004)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords: idiopathic pulmonary fibrosis, pulmonary fibrosis, pathophysiology, extracellular matrix, alveolar architecture, disease-modifying therapy, diagnosis, treatment options, respiratory failure
MeSH terms: Humans, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Idiopathic pulmonary fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks